News - Biosimilars

Filter

Current filters:

Biosimilars

Popular Filters

1 to 25 of 76 results

USA’s GPhA and numerous other groups lodge concerns on biosimilars names

USA’s GPhA and numerous other groups lodge concerns on biosimilars names

02-07-2014

A total of 32 organizations have signed a letter calling on the US Food and Drug Administration to require…

BiosimilarsBiotechnologyRegulationUSA

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

30-06-2014

Cipla has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin…

ActoriseAmgenAranespBiosimilarsCiplaGenericsHeteroIndiaMarkets & MarketingMergers & AcquisitionsOncologyRest of the World

JHL Biotech’s new $35 million financing will fund biosimilars

JHL Biotech’s new $35 million financing will fund biosimilars

22-06-2014

Taiwan biopharma company JHL Biotech say it has closed a Series B financing round of $35 million, led…

Asia-PacificBiosimilarsBiotechnologyFinancialJHL BiotechProductionResearch

Study reveals factors supporting a sustainable European biosimilar medicines market

Study reveals factors supporting a sustainable European biosimilar medicines market

13-06-2014

Biosimilar medicines will deliver an opportunity for increased access to better healthcare for patients…

AvastinBiosimilarsEuropeHealthcareHerceptinHumiraRegulation

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

12-06-2014

USA-based privately-held Epirus Biopharmaceuticals, focused on the development and commercialization…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBOW015EPIRUS BiopharmaceuticalsinfliximabRemicadeResearch

Lucrative biosimilars space to erode biologics market from 2019

Lucrative biosimilars space to erode biologics market from 2019

11-06-2014

The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market…

BiosimilarsBiotechnologyGlobalMarkets & MarketingRegulation

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

Generic and biosimilar drugs should be key components of CSRs for health, says EGA

Generic and biosimilar drugs should be key components of CSRs for health, says EGA

05-06-2014

The increased number of health related proposed country specific recommendations (CSR) to European Union…

BiosimilarsGenericsHealthcareRegulation

European generics group welcomes WHA resolution on biotherapeutics products

04-06-2014

The European Generic Medicines Association (EGA) has welcomed the 67th World Health Assembly’s Resolution…

BiosimilarsGenericsGlobalRegulation

European and Japanese generics groups view opportunities on biosimilars

European and Japanese generics groups view opportunities on biosimilars

29-05-2014

The European Generic Medicines Association (EGA) participated in several meetings with Japanese government…

BiosimilarsEuropeGenericsJapanMarkets & MarketingRegulation

India encouraging opportunities for biotech innovation

India encouraging opportunities for biotech innovation

27-05-2014

In a bid to encourage new and innovative ideas for research and commercialization, the Indian government's…

BiosimilarsBiotechnologyFinancialIndiaResearch

Russian PM visits country's first commercial manufacturing plant for MAb-based therapeutic proteins

20-05-2014

Russian Prime Minister Dmitri Medvedev on Monday visited the commercial manufacturing facility for monoclonal…

BiocadBiosimilarsGenericsOncologyProductionRussia

Biocad’s AcellBia is first MAb biosimilar approved by Russia’s Ministry of Health

15-05-2014

A biosimilar of Swiss drug major Roche’s MabThera (rituximab), to be marketed under the trade name…

AcellBiaBiocadBiosimilarsGenericsMabTheraOncologyRegulationRocheRussia

Actavis announces proposed Senior Leadership Team

Actavis announces proposed Senior Leadership Team

14-05-2014

US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead…

ActavisBiosimilarsBoardroomForest LaboratoriesPharmaceuticalUSA

ABPI updates recommendations on use of biosimilars

ABPI updates recommendations on use of biosimilars

14-05-2014

The UK trade body the Association of British Pharmaceutical Industries (ABPI) has launched the third…

Association of British Pharmaceutical IndustriesBiosimilarsClinical researchHealthcarePharmaceutical sciencesPharmacologyUK

Merck KGaA may look to biosimilars and acquisitions for growth

Merck KGaA may look to biosimilars and acquisitions for growth

12-05-2014

German pharma and chemical major Merck KGaA has said it is planning to invest in innovations to ensure…

BiosimilarsLicensingMerck KGaAMergers & AcquisitionsPharmaceutical

Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar

07-05-2014

Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

Lupin inks strategic biosimilars joint venture agreement with Yoshindo

23-04-2014

Indian drugmaker Lupin has entered into a strategic joint venture agreement with Japanese pharma company,…

BiosimilarsBiotechnologyEnbrelInflammatory diseasesJapanLicensingLupinTakeda PharmaceuticalYoshindo

Epirus to acquire Zalicus, creating a publicly-traded biosimilars enterprise

16-04-2014

Boston-based privately-held Epirus Biopharmaceuticals, focused on the global development and commercialization…

BiosimilarsBiotechnologyEPIRUS BiopharmaceuticalsMergers & AcquisitionsZalicus

1 to 25 of 76 results

Back to top